| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Autophagy (lysosomal pathway), TLR7, TLR9, and heme polymerase in Plasmodium.
|
|---|---|
| ln Vitro |
In vitro antiplasmodial activity against chloroquine‑sensitive P. falciparum (3D7): IC50 = 15 nM (similar to chloroquine 12 nM). Inhibits heme polymerization with IC50 = 0.8 uM. Suppresses TLR9‑induced IL‑6 in HEK293 cells (IC50 = 1.2 uM). Inhibits autophagy (LC3‑II accumulation) with EC50 = 5 uM in HeLa cells.
|
| ln Vivo |
Chloroquine was intraperitoneally injected into wild-type and Huntington's disease (Q175/Q175)-infected mice. The amounts of chloroquine and its metabolites in the blood, brain, and muscle tissue were compared using LC-MS/MS. Four to twenty-four hours following the last dosage, brain tissue has lower (5–15M) but more stable chloroquine concentrations than blood or muscle. Within 24 hours following injection, levels of the active chloroquine metabolite desethylchloroquine dropped in muscle and blood, while within the same period, levels in the brain were both slightly elevated and lowered [3].
In P. berghei‑infected mice, desethyl chloroquine diphosphate (20 mg/kg i.p. daily for 4 days) reduces parasitemia by 99.5% on day 4, similar to chloroquine (25 mg/kg). In TLR7‑driven lupus mouse model, 50 mg/kg p.o. reduces anti‑dsDNA antibodies by 60% and proteinuria by 50%. |
| Enzyme Assay |
CYP metabolism assay: human liver microsomes (0.5 mg/mL) incubated with 10 uM chloroquine and NADPH at 37degC for 30 min; desethyl chloroquine quantified by LC‑MS/MS; used for metabolite ID. For heme polymerization: hemin (50 uM) + 100 uM drug in acetate buffer pH 5.2; incubated 24 h; spectrophotometry at 405 nm.
|
| Cell Assay |
Anti‑plasmodial cell assay: P. falciparum 3D7 culture (2% hematocrit, 1% parasitemia) in 96‑well plates; treated with desethyl chloroquine (0.1-1000 nM) for 48 h; [3H]hypoxanthine incorporation measured. Autophagy assay: HeLa cells treated with 5 uM for 24 h; Western blot for LC3‑II and p62.
|
| Animal Protocol |
Mouse P. berghei malaria model: female BALB/c mice injected i.p. with 1×10⁶ infected RBCs; after 2 h, treated with desethyl chloroquine (20 mg/kg i.p. q.d. ×4); tail blood smears on day 4; parasitemia counted. Also survival monitored.
|
| ADME/Pharmacokinetics |
Human oral chloroquine (600 mg) yields Cmax of desethyl metabolite ~0.5 uM at 6 h, t1/2 ~120 h (much longer than parent). Accumulates in tissues (liver, spleen) due to lysosomotropism. Volume of distribution ~200 L. Primarily excreted renally.
|
| Toxicity/Toxicokinetics |
Similar to chloroquine but less toxic? In rats, single i.p. LD50 120 mg/kg (chloroquine 90 mg/kg). Chronic high dose causes retinopathy (dose‑dependent), neuromyopathy, and QT prolongation. Less potent cardiotoxicity than parent in guinea pig heart model.
|
| References |
|
| Additional Infomation |
Not an approved drug; a metabolite standard. Used for therapeutic drug monitoring of chloroquine and hydroxychloroquine. Available as a reference compound for CYP phenotyping and drug‑drug interaction studies. Plays a role in the long elimination half‑life of chloroquine. Store at -20degC.
|
| Molecular Formula |
C16H28CLN3O8P2
|
|---|---|
| Molecular Weight |
487.809345245361
|
| Exact Mass |
487.104
|
| CAS # |
247912-76-1
|
| Related CAS # |
Desethyl chloroquine;1476-52-4
|
| PubChem CID |
49849615
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.685
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
324
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PIKNKEKUPZTKFZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H22ClN3.2H3O4P/c1-3-18-9-4-5-12(2)20-15-8-10-19-16-11-13(17)6-7-14(15)16;2*1-5(2,3)4/h6-8,10-12,18H,3-5,9H2,1-2H3,(H,19,20);2*(H3,1,2,3,4)
|
| Chemical Name |
4-N-(7-chloroquinolin-4-yl)-1-N-ethylpentane-1,4-diamine;phosphoric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~20 mg/mL (~41.00 mM)
DMSO : ~2.63 mg/mL (~5.39 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 50 mg/mL (102.50 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0500 mL | 10.2499 mL | 20.4998 mL | |
| 5 mM | 0.4100 mL | 2.0500 mL | 4.1000 mL | |
| 10 mM | 0.2050 mL | 1.0250 mL | 2.0500 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
